Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thiabendazole is a synthetic benzimidazole derivative and a small molecule anthelmintic (anti-worm) and antifungal agent. It is primarily used to treat infections caused by nematodes such as threadworm (Strongyloides stercoralis), pinworm (Enterobius vermicularis), hookworm, whipworm, roundworm, and trichinosis. Thiabendazole acts by inhibiting the mitochondrial enzyme fumarate reductase in susceptible organisms, disrupting their energy metabolism. It also functions as a chelating agent for certain metal poisonings and has been used as a post-harvest fungicide in agriculture. The drug was first introduced in 1962 and is considered the drug of choice for strongyloidiasis[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Thiabendazole.